Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/8/2025 | $365.00 | Outperform | Oppenheimer |
6/16/2025 | $365.00 | Buy | Truist |
5/30/2025 | $380.00 | Buy | Goldman |
5/13/2025 | $350.00 | Peer Perform → Outperform | Wolfe Research |
4/29/2025 | Outperform → Peer Perform | Wolfe Research | |
3/6/2025 | $340.00 | Outperform | RBC Capital Mkts |
11/6/2024 | $300.00 | Outperform | Bernstein |
5/30/2024 | $235.00 | Buy | Redburn Atlantic |
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
From Pod to Pantone: Omnipod Mango becomes an iconic color First of its kind collaboration celebrates individualism and a personal journey toward empowerment for people living with diabetes Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, and Pantone®, the global authority on color and provider of professional color standards for the design industries, today announced the creation of Omnipod Mango, a bright and joyful tropical orange yellow. Omnipod Mango was uniquely selected to celebrate the radiance of the diabetes community and symbolizes Insulet's passion and commitment to impro
Flavia Pease Appointed Chief Financial Officer Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Flavia Pease will succeed Ana Maria Chadwick as Executive Vice President, Chief Financial Officer, effective September 30, 2025. Ms. Chadwick will become a Senior Advisor to Insulet to ensure a smooth transition. "I want to personally thank Ana, who has provided steady and thoughtful leadership for Insulet during a period of significant growth," said Ashley McEvoy, Insulet President and Chief Executive Officer. "She has been instrumental in strengthening our financial
Company Further Strengthens Leadership Team with Appointment of Chief Growth Officer Manoj Raghunandanan Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Eric Benjamin to Chief Operating Officer effective immediately. The Company also announced the appointment of Manoj Raghunandanan as Chief Growth Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250825870386/en/Eric Benjamin, Insulet Chief Operating Officer In this expanded role, Mr. Benjamin will lead Insulet's end-to-end growth and
8-K - INSULET CORP (0001145197) (Filer)
144 - INSULET CORP (0001145197) (Subject)
10-Q - INSULET CORP (0001145197) (Filer)
Oppenheimer resumed coverage of Insulet with a rating of Outperform and set a new price target of $365.00
Truist initiated coverage of Insulet with a rating of Buy and set a new price target of $365.00
Goldman initiated coverage of Insulet with a rating of Buy and set a new price target of $380.00
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
Flavia Pease Appointed Chief Financial Officer Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Flavia Pease will succeed Ana Maria Chadwick as Executive Vice President, Chief Financial Officer, effective September 30, 2025. Ms. Chadwick will become a Senior Advisor to Insulet to ensure a smooth transition. "I want to personally thank Ana, who has provided steady and thoughtful leadership for Insulet during a period of significant growth," said Ashley McEvoy, Insulet President and Chief Executive Officer. "She has been instrumental in strengthening our financial
Company Further Strengthens Leadership Team with Appointment of Chief Growth Officer Manoj Raghunandanan Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Eric Benjamin to Chief Operating Officer effective immediately. The Company also announced the appointment of Manoj Raghunandanan as Chief Growth Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250825870386/en/Eric Benjamin, Insulet Chief Operating Officer In this expanded role, Mr. Benjamin will lead Insulet's end-to-end growth and
Expects to Exceed First Quarter Revenue Guidance and Raise Full Year 2025 Guidance Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Ms. McEvoy succeeds Jim Hollingshead, who has agreed with Insulet's Board of Directors that his employment with the Company will cease effective as of April 28, 2025, and resigned from the Insulet Board of Directors. The Insulet Board and Mr. Hollingshead mutually agreed that now is the rig
Raising Full Year Revenue and Adjusted Operating Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2025. Second Quarter Financial Highlights: Revenue of $649.1 million, up 32.9%, or 31.3% in constant currency, exceeds the high end of the Company's guidance range of 26.0% in constant currency Total Omnipod revenue of $639.0 million, up 33.0%, or 31.4% in constant currency U.S. Omnipod revenue of $453.2 million, up 28.7% International Omnipod revenue of $185.8 million, up 45.0%, or 38.8% in cons
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2025 on August 7, 2025, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2
Raising Full Year Revenue and Gross Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2025. "Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet's new President and CEO, I see a path to scale the Company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our P
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)